Genomind
Genomind LLC: A US-based personalized medicine firm specializing in saliva-based neuropsychiatric biomarker tests.
Founded
2009Genomind LLC: A US-based personalized medicine firm specializing in saliva-based neuropsychiatric biomarker tests.
Genomind LLC, founded with a mission to advance personalized medicine, specializes in developing neuropsychiatric disease biomarker tests. The company offers saliva-based tests that analyze neurotransmitter variations, providing detailed analytical reports to support individualized treatment plans. Genomind's core focus is on improving mental health outcomes through precision medicine, serving a diverse market that includes individuals, healthcare providers, ACOs, employers, health plans, and international clients.
Notable figures affiliated with Genomind include experts in neuropsychiatry and pharmacogenetics. The company has attracted significant investment from healthcare-focused venture capital firms. Key achievements include the successful implementation of their pharmacogenetic testing solutions and precision medicine software, which have been widely adopted by healthcare providers. Genomind's impact is evident in its contribution to personalized mental health treatment, enhancing patient care and outcomes through scientifically-backed, individualized approaches.
Companies similar to Genomind include Polaris Genomics, Genomenon, SureGene and Geneticure.
Genomind was founded in 2009.
Genomind's headquarters is located in King of Prussia, PA, US.
Genomind's most recent funding round was for $20.6M (USD) in September 2020.
As of Sep 17, 2020, Genomind has disclosed funding of $74M (USD). Undisclosed round amounts are excluded.
Genomind has 1,000 employees as of Feb 5, 2024.
geneticure.com
